<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pregabalin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pregabalin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pregabalin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11441" href="/d/html/11441.html" rel="external">see "Pregabalin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="117868" href="/d/html/117868.html" rel="external">see "Pregabalin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F949926"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lyrica;</li>
<li>Lyrica CR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868697"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Pregabalin;</li>
<li>AG-Pregabalin;</li>
<li>APO-Pregabalin;</li>
<li>Auro-Pregabalin;</li>
<li>DOM-Pregabalin;</li>
<li>JAMP-Pregabalin;</li>
<li>Lyrica;</li>
<li>M-Pregabalin;</li>
<li>Mar-Pregabalin;</li>
<li>MINT-Pregabalin;</li>
<li>NAT-Pregabalin;</li>
<li>NRA-Pregabalin;</li>
<li>PMS-Pregabalin;</li>
<li>RIVA-Pregabalin;</li>
<li>SANDOZ Pregabalin;</li>
<li>TARO-Pregabalin;</li>
<li>TEVA-Pregabalin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F949931"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous;</li>
<li>
                        GABA Analog</li></ul></div>
<div class="block doa drugH1Div" id="F949965"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>For patients with respiratory disease, initiate therapy at the lowest dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63eca950-fb2d-4d31-9e25-43026567d145">Cough, chronic refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough, chronic refractory (alternative agent) (off-label use):</b> Immediate release: <b>Oral:</b> Initial: 75 mg once daily; may increase gradually over the first week in increments of 75 mg/day based on response and tolerability up to a maximum of 300 mg/day in 3 divided doses (eg, 75 mg in morning and midday with 150 mg in the evening) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26447687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26447687'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ad982f6-abe6-4e23-89e9-30b803d922e2">Fibromyalgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia</b>
<b>(alternative agent): Note: </b>For patients who do not respond to or tolerate preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 75 mg twice daily; may increase to 150 mg twice daily within 1 week based on response and tolerability; maximum dose: 450 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Some experts suggest lower initial doses of 25 to 50 mg at bedtime; some patients may respond to maintenance doses &lt;300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (alternative agent) (off-label use): Note:</b> Monotherapy or adjunctive therapy for patients who do not tolerate or respond to preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24713617','lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24713617','lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 150 mg/day in 2 to 3 divided doses; may increase based on response and tolerability at weekly intervals in increments of 150 mg/day up to a usual dose of 300 mg/day. May further increase up to 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24290532','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24290532','lexi-content-ref-35900161'])">Ref</a></span>); however, additional benefit of doses &gt;300 mg/day is uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19737439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19737439'])">Ref</a></span>). <b>Note:</b> Some experts suggest a lower initial dose of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="393e56f7-bded-45b3-b486-3009d2e7543b">Neuropathic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>General dosing recommendations:</i></b> Immediate release: <b>Oral:</b> Initial: 25 mg once daily or 50 to 150 mg/day in 2 to 3 divided doses; may increase in increments of 25 to 150 mg/day at weekly intervals based on response and tolerability up to a usual dose of 300 to 600 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25479151','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25479151','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Cancer-associated neuropathy (monotherapy or combination therapy) (off-label use):</i> Oral:</b> Immediate release: Initial: 50 to 75 mg twice daily; increase over 1 to 2 weeks based on response and tolerability up to 300 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23577077','lexi-content-ref-21745832','lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23577077','lexi-content-ref-21745832','lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Critically ill ICU patients (monotherapy or combination therapy) (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For critically ill patients with neuropathic pain, pregabalin may be a useful component of multimodal pain control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: 75 mg once or twice daily; maintenance dose: 150 to 300 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tietze.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Diabetic neuropathy:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 75 to 150 mg/day in 2 to 3 divided doses; may increase daily dose in 75 mg increments every ≥3 days based on response and tolerability up to a maximum dose of 300 to 450 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27999003','lexi-content-ref-Feldman.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27999003','lexi-content-ref-Feldman.1','lexi-content-ref-manu.1'])">Ref</a></span>). Higher doses up to 600 mg/day may have greater adverse effects without additional benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28967801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28967801'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: 165 mg once daily; may increase within 1 week based on response and tolerability up to maximum dose of 330 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Postherpetic neuralgia:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 150 mg/day in divided doses (75 mg twice daily or 50 mg 3 times daily); may increase to 300 mg/day within 1 week based on response and tolerability; after 2 to 4 weeks, may further increase up to the maximum dose of 600 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: 165 mg once daily; may increase to 330 mg once daily within 1 week based on response and tolerability; after 2 to 4 weeks, may further increase up to the maximum dose of 660 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Spinal cord injury-associated neuropathic pain:</i></b> Immediate release: Oral: Initial: 75 mg twice daily; may increase within 1 week based on response and tolerability to 150 mg twice daily; after 2 to 3 weeks, may further increase up to a maximum of 600 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6545edec-78ea-47f0-a591-2f6ccea5471b">Pruritus, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus, chronic (alternative agent) (off-label use): Note:</b> For patients with pruritus resistant to preferred therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27206757','lexi-content-ref-22790094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27206757','lexi-content-ref-22790094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Neuropathic (eg, brachioradial pruritus, notalgia paresthetica) or malignancy related:</b></i> Based on limited data: Immediate release: <b>Oral:</b> Initial: 75 mg twice daily; may increase based on response and tolerability up to 150 to 300 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28168835','lexi-content-ref-Fazio.2018','lexi-content-ref-27206757','lexi-content-ref-27824228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28168835','lexi-content-ref-Fazio.2018','lexi-content-ref-27206757','lexi-content-ref-27824228'])">Ref</a></span>). Higher doses up to 600 mg/day have been used in oncology populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dalal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dalal.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Uremic:</i></b> Immediate release: <b>Oral:</b> Variable dosing has been used and includes: 50 mg every other day given after dialysis on hemodialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27397522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27397522'])">Ref</a></span>) or 25 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.1','lexi-content-ref-36377169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.1','lexi-content-ref-36377169'])">Ref</a></span>), each increased based on response and tolerability to 50 or 75 mg daily. 75 mg twice weekly given after dialysis on hemodialysis days also appears effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25099523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25099523'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (off-label use):</b> Immediate release: <b>Oral:</b> Initial: 50 to 75 mg once daily, 1 to 3 hours before bedtime; gradually increase (eg, in increments of 75 to 150 mg) every 5 to 7 days based on response and tolerability to a usual effective dose of 150 to 450 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20466589','lexi-content-ref-24521108','lexi-content-ref-24899755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20466589','lexi-content-ref-24521108','lexi-content-ref-24899755'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b3f1d16-f7e6-430c-b42d-73b52a9ae376">Seizures, focal onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures</b>
<b>, focal (partial) onset (adjunctive therapy with other antiseizure medications):</b> Immediate release: <b>Oral:</b> Initial: 150 mg/day in 2 or 3 divided doses; may increase based on response and tolerability at weekly intervals up to a maximum dose of 600 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (alternative agent) (off-label use):</b>
<b>Note:</b> Monotherapy or adjunctive therapy for patients who do not tolerate or respond to preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.1'])">Ref</a></span>). Immediate release: <b>Oral:</b> Initial: 100 mg 3 times daily; may increase over 1 week in increments of 150 mg/day based on response and tolerability up to 600 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21368587','lexi-content-ref-21734588','lexi-content-ref-15206660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21368587','lexi-content-ref-21734588','lexi-content-ref-15206660'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent) (off-label use): Note:</b> Used as a nonhormonal alternative in patients unable or unwilling to take preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26444994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26444994'])">Ref</a></span>). Some experts prefer gabapentin over pregabalin as an alternative agent because of greater available evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Santen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Santen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 50 mg once daily at bedtime; may increase at weekly intervals based on response and tolerability to 50 mg twice daily, and then up to 75 mg twice daily; may further increase up to 150 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19901102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19901102'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Dosing conversion </b></i>
<b>
<i>from immediate-release oral formulations to extended-release oral formulation:</i> Note: </b>On the day of the switch, administer morning dose of immediate-release product as prescribed, and initiate extended-release therapy after the evening meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 75 mg is equivalent to extended-release dose of 82.5 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 150 mg is equivalent to extended-release dose of 165 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 225 mg is equivalent to extended-release dose of 247.5 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 300 mg is equivalent to extended-release dose of 330 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 450 mg is equivalent to extended-release dose of 495 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release total daily dose of 600 mg is equivalent to extended-release dose of 660 mg once daily</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> According to the manufacturer, in patients receiving pregabalin chronically, pregabalin should be withdrawn gradually over ≥1 week unless safety concerns require a more rapid withdrawal to minimize the potential of increased seizure frequency (in patients with epilepsy) or other withdrawal symptoms (eg, agitation, confusion, delirium, delusions, GI symptoms, mood changes, sweating, withdrawal seizures). For patients with epilepsy, some experts recommend discontinuing over 3 to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28988943','lexi-content-ref-22822593','lexi-content-ref-Sirven.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28988943','lexi-content-ref-22822593','lexi-content-ref-Sirven.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose: Oral, extended release:</b> If evening meal dose is missed, administer before bedtime following a snack. If missed before bedtime, administer in the morning with a meal. If missed in the morning, wait until the evening meal to take the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991155"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Pregabalin Dose Adjustments in Altered Kidney Function<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl<sup>c</sup></p></th>
<th align="center" colspan="5">
<p style="text-indent:0em;">Immediate release</p></th>
<th align="center" colspan="5">
<p style="text-indent:0em;">Extended release</p></th></tr>
<tr>
<th align="center" colspan="4">
<p style="text-indent:0em;">Usual indication-specific recommended dose</p></th>
<th align="center">
<p style="text-indent:0em;">Dosing frequency</p></th>
<th align="center" colspan="4">
<p style="text-indent:0em;">Usual indication-specific recommended dose</p></th>
<th align="center">
<p style="text-indent:0em;">Dosing frequency</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="11">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Manufacturer’s labeling.</p></td></tr>
<tr>
<td align="center" colspan="11">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Choose usual dose based on indication (see "Dosing: Adult"), then choose the adjusted dose from the column corresponding to the patient's CrCl.</p></td></tr>
<tr>
<td align="center" colspan="11">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Estimated by Cockcroft-Gault equation.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>≥60 mL/minute (normal kidney function)</b></p></td>
<td align="center">
<p style="text-indent:0em;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 divided doses</p></td>
<td align="center">
<p style="text-indent:0em;">165 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">330 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">495 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">660 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>30 to &lt;60 mL/minute</b></p></td>
<td align="center">
<p style="text-indent:0em;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">225 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 divided doses</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">165 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">247.5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">330 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>15 to &lt;30 mL/minute</b></p></td>
<td align="center">
<p style="text-indent:0em;">25 to 50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">100 to 150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 divided doses</p></td>
<td align="center" colspan="5" rowspan="2">
<p style="text-indent:0em;">Use not recommended (convert to pregabalin immediate release).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>&lt;15 mL/minute</b></p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">25 to 50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">50 to 75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">Single daily dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> No dosage adjustment necessary; however, may consider increasing dose by 25% if poor response followed by a return to normal dosing as CrCl returns to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50% to 60%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12638396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12638396'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In a large observational cohort study, pregabalin use in hemodialysis was associated with up to a 51% and 68% higher risk of altered mental status and falls, respectively, compared to no use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29871945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29871945'])">Ref</a></span>). This association was statistically significant, even in dose ranges of ≤100 mg/day. Use pregabalin cautiously in hemodialysis patients at the lowest effective dose with close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<b>Immediate release:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daily dosing:</i> Initial: 25 mg once daily, may titrate gradually based on tolerability and response to a maximum of 75 mg daily; administer after hemodialysis on dialysis days. A supplemental dose is not needed unless the usual daily dose is administered prior to the dialysis session; if this occurs, a supplementary posthemodialysis dose (50% to 100% of the usual daily dose) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12638396','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12638396','lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Three times weekly (posthemodialysis) dosing:</i> 25 to 75 mg administered 3 times weekly after hemodialysis on dialysis days has been found to be effective for peripheral neuropathy and uremic pruritus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27397522','lexi-content-ref-28057164','lexi-content-ref-26957874','lexi-content-ref-27824127','lexi-content-ref-25864854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27397522','lexi-content-ref-28057164','lexi-content-ref-26957874','lexi-content-ref-27824127','lexi-content-ref-25864854'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release: </b>Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Initial: 25 mg once daily, may titrate gradually based on tolerability and response to a maximum of 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use cautiously at the lowest effective dose with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of action is CNS) and indication (eg, antiseizure, analgesic). Close monitoring of response and adverse reactions (eg, confusion, myoclonus, altered mental status) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although not studied in patients receiving CRRT, significant removal of pregabalin is expected based on pharmacokinetic properties (eg, small V<sub>d</sub>, low protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27546759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27546759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Initial: 50 to 75 mg/day in 1 to 2 divided doses; titrate gradually based on tolerability and response up to a maximum of 300 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of action is CNS) and indication (eg, antiseizure, analgesic). Close monitoring of response and adverse reactions (eg, confusion, myoclonus, altered mental status) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although not studied in patients receiving PIRRT, significant removal of pregabalin is expected based on pharmacokinetic properties (eg, small V<sub>d</sub>, low protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b></p>
<p style="text-indent:-2em;margin-left:6em;">PIRRT days: Initial: 50 to 75 mg/day in 1 to 2 divided doses; titrate gradually based on tolerability and response up to a maximum of 300 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: 25 to 75 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988511"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, no adjustment is expected since undergoes minimal hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F1623542"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Initiate therapy at the lowest dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>). Refer to adult dosing; use with caution. In the management of restless legs syndrome, a starting dose of 50 mg once daily in patients &gt;65 years has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F51451290"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="117868" href="/d/html/117868.html" rel="external">see "Pregabalin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> When discontinuing, taper off gradually over at least 1 week.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42dcb5f5-e8d5-4286-9bb5-f280e0e04481">Seizures, partial onset; adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, partial onset; adjunctive therapy:</b> Immediate release:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;4 years weighing &lt;30 kg: Oral: Initial dose: 3.5 mg/kg/day in 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 14 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents &lt;17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: Oral: Initial dose: 3.5 mg/kg/day in 2 or 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 14 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: Oral: Initial dose: 2.5 mg/kg/day in 2 or 3 divided doses; dose may be increased weekly based on clinical response and tolerability; maximum daily dose: 10 mg/kg/<b>day</b> not to exceed 600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Oral: Initial dose: 150 mg daily in 2 or 3 divided doses; may be increased weekly based on tolerability and effect; maximum daily dose: 600 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ad982f6-abe6-4e23-89e9-30b803d922e2">Fibromyalgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia:</b> Limited data available: Immediate release: Children ≥12 years and Adolescents: Oral: Initial: 37.5 mg twice daily for 1 week, then titrate based on clinical response and tolerability to 150 to 450 mg/day in 2 divided doses; maximum daily dose: 450 mg/<b>day</b>. Dosing based on a multi-center, double-blind, placebo-controlled trial (15 weeks) and secondary open-label continuation trial (6 months) (n=107; pregabalin n=54; age range: 12 to 17 years); total daily doses were titrated weekly to an individually optimized dose of 150 mg/day, 300 mg/day, or 450 mg/day; maximum daily dose: 450 mg/<b>day</b>; mean dose during maintenance phase of double-blind study was 244.5 mg/day and in the open label trial it was 254.3 mg/day. Although the primary endpoint of change in mean pain scores from baseline to week 15 was not statistically significant, there was a trend toward improvement in the pregabalin group. Change in weekly mean pain scores was significantly greater with pregabalin compared to placebo for 10 of the 15 weeks; the patient global impression of change was also significantly improved in patients receiving pregabalin (53.1%) compared to placebo (29.5%). The authors reported a large placebo effect, particularly at non-US study centers; however, significance of this is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27475753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27475753'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51435906"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Immediate release: There are no pediatric-specific dosage adjustments provided in manufacturer's labeling (has not been studied); based on experience in adult patients, dosing adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51435907"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; however, no adjustment is expected since pregabalin undergoes minimal hepatic metabolism.</p></div>
<div class="block arsc drugH1Div" id="F54504769"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS and respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-dependent CNS depression may occur and present as somnolence<b>, dizziness</b>, and/or <b>drowsiness</b>. In addition, serious, life-threatening, and fatal <b>respiratory depression</b> may occur; most cases occurred with concomitant use of CNS depressants (especially opioids) in the setting of underlying respiratory impairment or in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>). CNS depression may impair physical or mental abilities and result in <b>accidental injury, </b>including falls.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to pharmacologic action (ie, structurally related to GABA).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; timing impacted by concomitant use of medications known to cause CNS depression (eg, opioids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of alcohol or other CNS depressants (eg, opioids, benzodiazepines, antidepressants, antihistamines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with underlying respiratory impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elderly patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2019'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isolated cases of delayed hypersensitivity reactions have been reported ranging from <b>maculopapular rashes</b> to severe cutaneous adverse reactions (SCARs), namely <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS syndrome), <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29027197','lexi-content-ref-26976337','lexi-content-ref-31604720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29027197','lexi-content-ref-26976337','lexi-content-ref-31604720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; immunologic. Delayed hypersensitivity reactions are mediated by T-cells or antibodies other than IgE (eg, IgG-mediated, such as some cytopenias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). SCARs are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied. Type IV reactions are delayed hypersensitivity reactions that typically occur days to weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior history of delayed hypersensitivity reaction to pregabalin. <b>Note: </b>It is unknown whether cross-reactivity exists between gabapentin and pregabalin, given their similar structures. Gabapentinoids are usually considered safe agents for patients with a previous history of drug allergies to other antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10199060','lexi-content-ref-11307046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10199060','lexi-content-ref-11307046'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral edema </b>may occur in patients with or without a prior history of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21644108','lexi-content-ref-23128284','lexi-content-ref-21747401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21644108','lexi-content-ref-23128284','lexi-content-ref-21747401'])">Ref</a></span>). In patients with a prior history of heart failure, peripheral edema may result in acute decompensated heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18507657','lexi-content-ref-24769529','lexi-content-ref-18695430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18507657','lexi-content-ref-24769529','lexi-content-ref-18695430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to pharmacologic action. Exact mechanism not fully established; a possible mechanism may be antagonism of the L-type calcium channels which results in vasodilation of mesenteric resistance arteries. The resultant increased intracapillary hydrostatic pressure leads to increased fluid in the interstitium and peripheral edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984','lexi-content-ref-18695430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984','lexi-content-ref-18695430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied. Onset of symptoms within days of initiation has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18507657','lexi-content-ref-24769529','lexi-content-ref-18695430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18507657','lexi-content-ref-24769529','lexi-content-ref-18695430'])">Ref</a></span>); whereas, other reports describe onset of symptoms after months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21747401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21747401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of thiazolidinedione antidiabetic agents, particularly in patients with prior cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that may increase risk of peripheral edema</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting heart failure (NYHA Class III or IV) (cautious use recommended due to limited data in this patient population)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation and tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal ideation and suicidal tendencies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; exact mechanism is not established. Theories include lowering of the threshold for manifesting psychiatric symptoms in patients susceptible to psychiatric disorders or antiseizure-induced disinhibition and impulsiveness thereby influencing and promoting suicidal acts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30488008','lexi-content-ref-21479999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30488008','lexi-content-ref-21479999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>As early as 1 week after initiation of antiseizure drugs, including gabapentin</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for suicidal thoughts and behaviors (including epilepsy)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of psychiatric disorders or aggressive behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30488008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30488008'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Visual disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blurred vision</b>, <b>decreased visual acuity</b>, amblyopia,<b> diplopia</b>, and <b>visual field loss </b>have been associated with therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21320112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21320112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; likely involves vestibulocerebellar and/or brainstem structures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21320112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21320112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; effect is dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21320112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21320112'])">Ref</a></span>); therefore, timing may be impacted by high doses or accumulation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions which may lead to accumulation (eg, kidney impairment, elderly patients, drug interactions)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use may cause <b>weight gain</b>. In clinical trials, as highlighted by the manufacturer, average weight gain was 5.2 kg for patients with diabetes receiving pregabalin for ≥2 years. The manufacturer reports that weight gain is not limited to patients with edema and does not appear to be associated with baseline BMI, gender, age, or loss of glycemic control in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related; exact mechanism is unknown. Some observations from preclinical studies suggest that pregabalin may result in an increase in appetite and abdominal fat (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22494020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22494020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: Delayed; </i>a pooled analysis aimed at characterizing long-term weight change in pregabalin-treated patients found that 1 in 6 patients who gained ≥7% weight from baseline generally exceeded this level 2 to 12 months after the onset of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22494020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22494020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F949941"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with adult patients, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (≤16%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Peripheral Edema table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-peripheral-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-peripheral-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Peripheral Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Peripheral Edema" frame="border" id="lexi-content-pregabalin-adverse-reaction-peripheral-edema" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Peripheral Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with spinal cord injury</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">174</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (≤14%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-weight-gain')">table 2</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Weight Gain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Weight Gain" frame="border" id="lexi-content-pregabalin-adverse-reaction-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">94</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">94</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with spinal cord injury</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">174</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3% to 45%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-dizziness')">table 3</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Dizziness</span>, drowsiness (≤36%; infants, children, and adolescents: 13% to 26%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-drowsiness')">table 4</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Drowsiness</span>, fatigue (4% to 11%), headache (2% to 14%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Dizziness" frame="border" id="lexi-content-pregabalin-adverse-reaction-dizziness" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">45%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with spinal cord injury</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">174</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Drowsiness" frame="border" id="lexi-content-pregabalin-adverse-reaction-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">71</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">94</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg/kg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy for partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">94</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with spinal cord injury</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">174</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">208</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">205</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Blurred Vision table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-blurred-vision" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-blurred-vision')">table 5</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Blurred Vision</span>, visual field loss (13%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Visual Field Loss table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-visual-field-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-visual-field-loss')">table 6</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Visual Field Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Blurred Vision" frame="border" id="lexi-content-pregabalin-adverse-reaction-blurred-vision" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Blurred Vision</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">378</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">502</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fibromyalgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with spinal cord injury</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">182</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">174</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Visual Field Loss" frame="border" id="lexi-content-pregabalin-adverse-reaction-visual-field-loss" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Visual Field Loss</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2%), edema (≤8%), facial edema (1% to 3%), hypertension (2%), hypotension (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (1%), ecchymoses (≥1%), pressure ulcer (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (≥1%), fluid retention (2% to 3%), hypoglycemia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (2%), abdominal pain (≥1%), constipation (3% to 10%), diarrhea (1%), flatulence (2% to 3%), gastroenteritis (≥1%), increased appetite (3% to 10%), nausea (3% to 5%), sialorrhea (children and adolescents: 1% to 4%), viral gastroenteritis (≤1%), vomiting (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (≤1%), impotence (≥1%), urinary frequency (≥1%), urinary incontinence (1% to 3%), urinary tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (3%, including severe thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤1%), increased serum aspartate aminotransferase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (6% to 8%), viral infection (infants and children: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (1% to 8%), abnormality in thinking (1% to 6%), amnesia (1% to 4%), anorgasmia (≥1%), ataxia (2% to 9%), balance impairment (2% to 9%), confusion (1% to 7%), depersonalization (≥1%), disorientation (1% to 2%), disturbance in attention (4% to 6%), euphoria (2% to 7%), feeling abnormal (1% to 3%), hypertonia (≥1%), hypoesthesia (2% to 3%), insomnia (4%), intoxicated feeling (1% to 2%), lethargy (1% to 2%), memory impairment (1% to 4%), myasthenia (1% to 5%), nervousness (1%), neuropathy (5%), pain (3% to 5%), paresthesia (2%), sedated state (≥1%), speech disturbance (1% to 3%), stupor (≥1%), twitching (≥1%; includes myokymia), vertigo (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 6%), asthenia (4% to 7%), increased creatine phosphokinase in blood specimen (2% to 3%), joint swelling (≤2%), lower limb cramp (≥1%), muscle spasm (4%), tremor (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≥1%), decreased visual acuity (7%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Decreased Visual Acuity table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-decreased-visual-acuity" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-decreased-visual-acuity')">table 7</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Decreased Visual Acuity</span>, diplopia (≤4%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Diplopia table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-diplopia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-diplopia')">table 8</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Diplopia</span>, eye disease (1% to 2%), nystagmus disorder (≥1%), visual disturbance (1% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Decreased Visual Acuity" frame="border" id="lexi-content-pregabalin-adverse-reaction-decreased-visual-acuity" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Decreased Visual Acuity</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Diplopia" frame="border" id="lexi-content-pregabalin-adverse-reaction-diplopia" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Diplopia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (≥1%), tinnitus (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (3%), dyspnea (2%), flu-like symptoms (2%), nasopharyngitis (1% to 8%), pharyngolaryngeal pain (3%), pneumonia (infants and children: 1% to 9%; adults: &lt;1%), respiratory tract infection (1%), sinusitis (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Pregabalin: Adverse Reaction: Accidental Injury table link" class="lexi-table-link" data-table-id="lexi-content-pregabalin-adverse-reaction-accidental-injury" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pregabalin-adverse-reaction-accidental-injury')">table 9</a>)</span><span class="table-link" style="display:none;">Pregabalin: Adverse Reaction: Accidental Injury</span>, fever (≥1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pregabalin: Adverse Reaction: Accidental Injury" frame="border" id="lexi-content-pregabalin-adverse-reaction-accidental-injury" rules="all">
<caption style="text-align:center;">
<b>Pregabalin: Adverse Reaction: Accidental Injury</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pregabalin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">321</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with diabetic peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">459</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neuropathic pain associated with postherpetic neuralgia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">398</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure, depression of ST segment on ECG, orthostatic hypotension, palpitations, retinal vascular disease, shock, syncope, tachycardia, thrombophlebitis, ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cellulitis, cutaneous nodule, dermal ulcer, eczema, erythema of skin, exfoliative dermatitis, lichenoid dermatitis, nail disease, pustular rash, skin atrophy, skin blister, skin necrosis, skin photosensitivity, skin rash, Stevens-Johnson syndrome (Frey 2017), subcutaneous nodule, urticaria, vesiculobullous dermatitis, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, decreased glucose tolerance, glycosuria, increased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, aphthous stomatitis, cholecystitis, cholelithiasis, colitis, dry mucous membranes, dysgeusia, dysphagia, esophageal ulcer, esophagitis, gastritis, gastrointestinal hemorrhage, hiccups, increased serum lipase, melena, oral mucosa ulcer, oral paresthesia, pancreatitis, periodontal abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder, oliguria, pelvic pain, proteinuria, retroperitoneal fibrosis, urate crystalluria, urinary retention, urine abnormality, uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, eosinophilia, granuloma, hemophthalmos, hypochromic anemia, hypoprothrombinemia, increased neutrophils, leukocytosis, leukopenia, lymphadenopathy, myelofibrosis, nonthrombocytopenic purpura, petechial rash, polycythemia, purpuric rash, rectal hemorrhage, thrombocythemia (rare) (Qu 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Ortega-Camarero 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation (coccydynia)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, agitation, apathy, aphasia, cerebellar syndrome, chills, cognitive dysfunction, cogwheel rigidity, delirium, delusion, drug dependence, dysarthria, dysautonomia, dystonia, encephalopathy, extraocular palsy, extrapyramidal reaction, hallucination, hangover effect, hostility, hypalgesia, hyperalgesia, hyperesthesia, hypotonia, impaired consciousness, irritability, malaise, myoclonus, neuralgia, psychomotor disturbance, sciatica, self-inflicted intentional injury, sleep disorder, trismus, yawning</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia, dyskinesia, hyperkinetic muscle activity, hypokinesia, joint stiffness, neck stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blindness, iritis, miosis, mydriasis, night blindness, periorbital edema, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure, glomerulonephritis, nephritis, nephrolithiasis, pyelonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolongation P-R interval on ECG (Schiavo 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Gunathilake 2013; Kato 2016; Kaufman 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Maculopapular rash (Inoue 2016), toxic epidermal necrolysis (rare: &lt;1%) (Frey 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Málaga 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (rare: &lt;1%) (Thein 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression (FDA Safety Alert, Dec 19, 2019)</p></div>
<div class="block coi drugH1Div" id="F949937"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, angioedema) to pregabalin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F949938"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Angioedema has been reported during initial and chronic treatment. Use with caution in patients with a history of angioedema episodes. Concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk. Discontinue treatment immediately if angioedema occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance misuse: Use with caution in patients with a history of substance misuse (Bonnet 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumorigenic potential: Increased incidence of hemangiosarcoma noted in animal studies; significance of these findings in humans is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: In patients receiving pregabalin chronically, unless safety concerns require a more rapid withdrawal, pregabalin should be withdrawn gradually over ≥1 week (Bonnet 2017; "Gabapentin and Pregabalin" 2012).</p></div>
<div class="block foc drugH1Div" id="F949971"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyrica: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyrica: 20 mg/mL (473 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyrica CR: 82.5 mg, 165 mg, 330 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 82.5 mg, 165 mg, 330 mg</p></div>
<div class="block geq drugH1Div" id="F949929"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422158"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lyrica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">225 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $11.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Pregabalin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.03 - $8.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.04 - $9.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.05 - $9.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.05 - $10.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.07 - $10.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.08 - $8.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">225 mg (per each): $0.08 - $8.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.10 - $8.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lyrica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $3.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pregabalin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $2.12 - $2.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Lyrica CR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">82.5 mg (per each): $19.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">165 mg (per each): $19.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $19.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Pregabalin ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">82.5 mg (per each): $10.62 - $20.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">165 mg (per each): $10.62 - $20.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $10.62 - $20.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868698"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyrica: 25 mg, 50 mg, 75 mg, 150 mg, 225 mg, 300 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 75 mg, 150 mg, 225 mg, 300 mg</p></div>
<div class="block csi drugH1Div" id="F949924"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-V</p></div>
<div class="block adm drugH1Div" id="F949967"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Administer once daily after an evening meal; swallow whole, do not split, crush, or chew. A missed dose should be administered before bedtime following a snack. If missed before bedtime, administer in the morning with a meal. If missed in the morning, wait until the evening meal to administer the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR capsule and solution formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR capsule or solution should be strongly considered for postherpetic neuralgia and seizures indications.</p></div>
<div class="block admp drugH1Div" id="F52614152"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate release: May be administered with or without food.</p></div>
<div class="block meg drugH1Div" id="F7874966"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Lyrica: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021446s041%2C022488s018lbl.pdf%23page%3D57&amp;token=Ta2fkPb3phwYAWyHK83tgCOsi9uxbuhZFf43Thl1X2Aafq%2Bu0qtjV2UqJ1C8tXEKcReWbcGVREBY5YMNZTbtGx%2BC6W%2FflNdqNv9wgpQL3I2TCUG5jjDOQOIaREOwAOiQ&amp;TOPIC_ID=9473" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021446s041,022488s018lbl.pdf#page=57</a></p>
<p style="text-indent:-2em;margin-left:4em;">Lyrica CR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F209501s005lbl.pdf%23page%3D31&amp;token=w04AAM6EgpZqDeuj6BTOziZYX5NYJtCTJo7Ujjd4Yyo8c4p5F53ihpTreoY69%2B7fNCZv%2Bm17SSTS9%2Fh9Wd4PNY6IQmG%2FDk5Rr1k9BBgaDT0Cg0RvZIXef3EYgvtLc0CM&amp;TOPIC_ID=9473" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209501s005lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F949932"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia (immediate release only):</b> Management of fibromyalgia</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release):</b> Management of neuropathic pain associated with diabetic peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain associated with spinal cord injury (immediate release only): </b>Management of neuropathic pain associated with spinal cord injury</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia (immediate release and extended release): </b>Management of postherpetic neuralgia</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, focal (partial) onset (immediate release only):</b> Adjunctive therapy in patients ≥1 month of age with focal onset (partial-onset) seizures</p></div>
<div class="block off-label drugH1Div" id="F25860679"><span class="drugH1">Use: Off-Label: Adult</span><p>Cancer-associated neuropathy; Cough, chronic refractory; Generalized anxiety disorder; Neuropathic pain, critically ill patients; Pruritus, neuropathic or malignancy related; Pruritus, uremic; Restless legs syndrome; Social anxiety disorder; Vasomotor symptoms associated with menopause</p></div>
<div class="block mst drugH1Div" id="F6881223"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lyrica may be confused with Hydrea, Lopressor</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used for neuropathic pain) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pregabalin (Lyrica) oral solution (20 mg/mL): Prescriptions should be written in terms of mg. The pharmacist will calculate the appropriate dose in mL for dispensing.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299940"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F949947"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Pregabalin may enhance the fluid-retaining effect of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F50802055"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Extended release: Bioavailability is reduced if taken on an empty stomach. The AUC is approximately 30% lower when fasting relative to following an evening meal. Management: Administer after evening meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F49321575"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In a study conducted in males, pregabalin was found to temporarily decrease mean sperm concentrations; no effects on sperm morphology or motility were observed. Concentrations increased after pregabalin was discontinued. The clinical relevance of this is not known.</p></div>
<div class="block pri drugH1Div" id="F949934"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregabalin crosses the placenta (Ohman 2011). Studies which evaluated neonatal outcomes following pregabalin exposure during pregnancy are limited (Mostacci 2017; Patorno 2017; Veiby 2014; Winterfeld 2016). Pregabalin has been evaluated as an adjuvant pain medication following cesarean section and pregnancy termination (El Kenany 2016; Lavand'homme 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to pregabalin is ongoing. Patients exposed to pregabalin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F20618123"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of pregabalin is ~7% when calculated using an average breast milk concentration compared to a weight-adjusted maternal dose of 300 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of pregabalin was calculated using an average milk concentration of 2.05 mcg/mL, providing an estimated daily infant dose via breast milk of 0.31 mg/kg/day. This milk concentration was obtained following maternal administration of pregabalin 150 mg orally twice daily for 4 doses. The study included 10 women who were ~37 weeks' postpartum (range: 15 to 81 weeks). Infants were not breastfed during the study period. Peak concentrations in breast milk were generally lower than those in the maternal plasma (Lockwood 2016). A slightly higher RID of ~8% was noted in a case report (Ohman 2011). Poor latching on, lasting ~8 hours, was observed in three infants immediately postpartum following a single maternal dose of pregabalin for pain during cesarean delivery (El Kenany 2016). Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F949969"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Measures of efficacy (pain intensity/seizure frequency); degree of sedation; mental alertness; symptoms of respiratory depression and sedation in patients with underlying respiratory disease (FDA 2019); symptoms of myopathy; creatine kinase (as clinically indicated); symptoms of ocular disturbance; weight gain/edema; skin integrity (in patients with diabetes); signs and symptoms of suicidality (eg, suicidal thoughts, anxiety, depression, behavioral changes); platelet count (as clinically indicated)</p></div>
<div class="block pha drugH1Div" id="F949963"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to alpha-2-delta subunit of voltage-gated calcium channels within the CNS and modulates calcium influx at the nerve terminals, thereby inhibiting excitatory neurotransmitter release including glutamate, norepinephrine (noradrenaline), serotonin, dopamine, substance P, and calcitonin gene-related peptide (Gajraj 2007; McKeage 2009). Although structurally related to GABA, it does not bind to GABA or benzodiazepine receptors. Exerts antinociceptive and antiseizure activity. Pregabalin may also affect descending noradrenergic and serotonergic pain transmission pathways from the brainstem to the spinal cord.</p></div>
<div class="block phk drugH1Div" id="F949952"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Pain management: Effects may be noted as early as the first week of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Extended release: AUC is approximately 30% lower when administered while fasting</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.5 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 0%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Negligible</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ≥90%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤6 years: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to &lt;17 years: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: 6.3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Median: 8 hours with food (range: 5 to 12 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months, Children, and Adolescents &lt;17 years: 0.5 to 2 hours fasting</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Within 1.5 hours fasting; ~3 hours with food</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (90% as unchanged drug; minor metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51220105"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clearance in pediatric patients weighing &lt;30 kg has been observed to be 40% higher than those weighing ≥30 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Oral clearance tends to decrease with increasing age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869449"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lebalix | Lyrgaba | Nervalin | Pregadex | Pregastar | Prex | Starica</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Axual | Axual dividosis | Balfibro | Clasica | Dolgenal | Doloneutin | Gavaneural | Gavin | Kabian | Kabian multidosis | Linprel | Lunel | Lyrica | Mystika | Neuristan | Pgb | Plenica | Plenica Practidosis | Prebanal | Prebictal | Prebien | Prebien Dividosis | Pregabalina Hlb | Pregabalina richet | Pregabalina vannier | Preganova | Principia | Principia 75 practidosis | Seripran</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Lyribastad | Lyrica | Pregabalin +pharma | Pregabalin accord | Pregabalin Dr. Reddy | Pregabalin genericon | Pregabalin krka | Pregabalin pfizer | Pregabalin ratiopharm | Pregabalin sandoz | Pregabalin stada | Pregamid | Pregatab</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adimedi pregabalin | Adimis pregabalin | Adirag pregabalin | Adiramedica pregabalin | Adiris pregabalin | Adrabalin pregabalin | Adranuro pregabalin | Adraprega pregabalin | Akm pregabalin | Algerika | Apo pregabalin | Blooms the chemist pregabalin | Btc pregabalin | Chemmart pregabalin | Cipgablin | Cipla pregabalin | Gabrica | Lypralin | Lyraccord | Lyrica | Lyrica cr | Lyrigalin | Lyrilin | Lyzalon | Neurica | Neuroccord | Noumed pregabalin | Pharmacor pregabalin | Prebalin | Pregabalin alphapharm | Pregabalin amneal | Pregabalin an | Pregabalin apotex | Pregabalin arw | Pregabalin ch | Pregabalin dr reddys | Pregabalin drla | Pregabalin gh | Pregabalin gppl | Pregabalin intas | Pregabalin jl | Pregabalin lapl | Pregabalin lupin | Pregabalin mylan | Pregabalin rz | Pregabalin sandoz | Pregabalin Teva | Pregabica | Pregaciplin | Pregaredi | Sudorega | Terry white chemists pregabalin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Gaba aid | Gabatec | Lirica | Lyric | Lyrinex | Lyrinex cr | Myrica | Nepco | Nerfid | Nervalin | Nervalin cr | Neugaba | Neugalin | Neurega | Neurica | Neurolin | Neurovan | Pegalin | Pegalin er | Pegaron | Pg | Prebalin | Pregaba | Pregaben | Pregadel | Pregalex | Pregan | Pregan er | Prelica | Prelin | Priga | Regab | Vaxar | Xablin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin ab | Pregabalin sandoz | Pregabaline apotex | Pregabaline eg | Pregabaline krka | Pregabaline mylan | Pregabaline teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Linefor | Pragiola | Pregabalin accord | Pregabalin Alvogen | Pregabalin mylan pharma | Pregabalin sandoz | Pregabin | Pregagamma | Siranalen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alond | Apice | Dorene | Gabalgin | Glya | Insit | Konduz | Limiar | Lyrica | Lysugi | Mobale | Neugaba | Prebictal | Prefiss | Pregabalina | Pregalpha | Preneurin | Proleptol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin axaphar | Pregabalin mepha | Pregabalin pfizer | Pregabalin sandoz | Pregabalin spirig hc | Pregabalin xiromed | Pregabalin zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Neurogil | Pregaben</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alivax | Lyrica | Neuropreg | Neurum | Pentinor | Plenica | Plenitex | Prebictal | Prefaxil | Pregabax | Pregalin | Pregastar | Pregobin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Xi si ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alond | Dolencar | Dolica | Epibalin | Gabadox | Gabalin | Gabapi | Legabin | Lyrica | Martesia | Maxgalin | Nervigaba | Neubalin | Neuprel | Neurixa | Prebalix | Prebictal | Pregabalina | Pregabyal | Pregalex | Pregavitae | Pregobin | Preludyo | Proclor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Kartesada | Lyrica | Naxalgan | Pragiola | Preato | Pregabalin accord | Pregabalin alpha | Pregabalin apotex | Pregabalin belupo | Pregabalin mylan | Pregabalin sandoz | Pregabalin stada | Pregabalin Teva | Pregabalin vivanta | Pregabalin zentiva | Pregagamma | Pregamid | Preglenix | Prelica | Rabakir | Siranalen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Algecia | Lyrica | Pregabador | Pregabahexal | Pregabalin 1A pharma | Pregabalin accord | Pregabalin acino | Pregabalin AL | Pregabalin alkem | Pregabalin amarox | Pregabalin aristo | Pregabalin ascend | Pregabalin aurobindo | Pregabalin axcount | Pregabalin axunio | Pregabalin basics | Pregabalin beta | Pregabalin biomo | Pregabalin glenmark | Pregabalin hennig | Pregabalin hormosan | Pregabalin mylan | Pregabalin neuraxpharm | Pregabalin pfizer | Pregabalin puren | Pregabalin ratiopharm | Pregabalin sandoz | Pregabalin stada | Pregabalin vivanta | Pregabalin zentiva | Pregabin | Pregagamma | Pregatab</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Doloneuropat | Eprevia | Finpal | Gabapi | Gabatin | Gacela | Kineptia | Lepsia | Linprel | Lyrica | Martesia | Neurocure | Nurolim AG | Pegabal | Prebictal | Pregab | Pregabalina | Pregabalina alfa | Pregabalina feltrex | Pregabalina mk | Pregabax | Pregagesic | Pregalex | Pregasafe | Pregaven | Pregox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Astik sr | Dis maxgalin | Dolopat | Garbican | Ibancheck | Kineptia | Legabin | Linprel | Linprel multidosis | Lyrica | Martesia | Maxgalin | Neurum | Plenica | Prebictal | Pregabalina | Pregabalina mk | Pregalex | Pregobin | Preludyo | Prestat | Zeugial</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Lyrica | Pragiola | Pregabalin accord | Pregabalin neuraxpharm | Pregabalin stada | Pregabalin zentiva | Pregagamma | Pregamid | Siranalen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andogablin | Averopreg | Balinozar | Convugabalin | Depapalin | Dragonor | Forpregab | Gablovac | Gapsolox | Globazure | Hexagabalin | Hexgabalin | Irenypathic | Kemirica | Lyribalin | Lyrica | Lyrineur | Lyrolin | Myafibrol | Nervagab | Nervatin | Nervatyca | Neuragabalin | Normolepsy | Olykraz | Painica | Pregaba | Pregabedium | Pregadin apex | Pregadurff | Pregatrend | Pregavalex | Pregdinapex | Prenervanex | Roviaprega | Serigabtin | Snapgab | Vronogabic</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aciryl | Frida | Gatica | Lyrica | Pramep | Prebalix | Pregabalina | Pregabalina accord | Pregabalina alter | Pregabalina apotex | Pregabalina aristo | Pregabalina Aurovitas | Pregabalina bexal | Pregabalina combix | Pregabalina HCS | Pregabalina kern pharma | Pregabalina krka | Pregabalina mabo | Pregabalina mylan | Pregabalina normon | Pregabalina pensa | Pregabalina qualigen | Pregabalina ranbaxy | Pregabalina ratiopharm | Pregabalina sandoz | Pregabalina stada | Pregabalina tarbis | Pregabalina Tecnigen | Pregabalina teva | Pregabalina tillomed | Pregabalina zentiva | Premax</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Neo gaba | Neurokem | Paden | Pregasafe | Probion | Zypane | Zypane SR</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lyribastad | Lyrica | Pregabalin 1a farma | Pregabalin accord | Pregabalin krka | Pregabalin mylan | Pregabalin orion | Pregabalin ratiopharm | Pregabalin sandoz | Pregabalin stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabaline accord | Pregabaline alter | Pregabaline arrow | Pregabaline biogaran | Pregabaline cristers | Pregabaline eg | Pregabaline evolugen | Pregabaline hcs | Pregabaline mylan | Pregabaline ranbaxy | Pregabaline Sandoz | Pregabaline teva | Pregabaline zentiva | Pregabaline zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alzain | Axalid | Lecaent | Lyrica | Pregabalin accord | Pregabalin amneal | Pregabalin aristo | Pregabalin aspire | Pregabalin focus | Pregabalin neuraxpharm | Pregabalin noumed | Pregabalin pfizer | Pregabalin ranbaxy | Pregabalin sandoz | Pregabalin sciecure | Pregabalin Teva | Pregabalin tillomed | Pregabalin wockhardt | Rewisca</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Algecia | Apregalin | Brieka | Egzysta | Lygabrin | Lyrica | Prebanel | Pregabalin mylan | Pregabalin sandoz | Pregabalin Teva | Pregabalin/vocate | Preganet | Siranalen</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Gabaneural</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo pregabalin | Lyrica | Pms pregabalin | Pregabalin actavis | Pregabalin sandoz | Pregatas | Prelynca | Rewisca</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pragiola | Pregabalin accord | Pregabalin pfizer | Pregabalin Pliva | Pregabalin sandoz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Egzysta | Naxalgan | Prabegin | Pragiola | Pregabalin richter | Pregabalin sandoz | Pregamid | Prenudol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aprion | Glinov | Labalin | Leptica | Lyrigad | Neufar | Nomathic | Pregamep | Provelyn</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Lyrica | Pregabalin accord | Pregabalin clonmel | Pregabalin krka | Pregabalin mylan | Pregabalin sandoz | Pregabalin Teva | Pregabalin wockhardt | Pregabalin zentiva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lyrica</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Avertz | Engaba | Esgaba | Esviga | Gabacure | Gabafit | Gabaniche | Gabawin | Gabawin er | Gablincad | Gb Lin | Lyrica | Maxgalin | Maxnerve pg | Neugaba | Neugalin | Neurica | Neurokem | Nevirin | New gb29 | Nova | Nuramed | Nurogab | P gaba 50 | Pbren | Pevesca | Prebeta sr | Prebid | Precarise | Preega | Pregaba | Pregabal | Pregabel | Pregabid | Pregacent | Pregacon | Pregader | Pregadoc | Pregalex | Pregalin | Pregalodos | Preganerve | Preganza | Pregaohm | Pregastar | Pregateo sr | Pregeb | Prejunate | Prelica | Preneurolin | Prixain | Recobal | Repagab | Resenz | Sonaxa | Trugaba | Zenerv | Zylin</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Lyrikine | Pregafix | Pregalin | Pregaline | Pregasaf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aclaton | Ecubalin | Gabex | Gaviria | Lyrica | Pregabalin accord | Pregabalin alter | Pregabalin aristo | Pregabalin aurobindo | Pregabalin doc generici | Pregabalin ecupharma | Pregabalin eg | Pregabalin hcs | Pregabalin mylan | Pregabalin pensa | Pregabalin ranbaxy | Pregabalin sandoz | Pregabalin tecnigen | Pregabalin teva italia | Pregabalin zentiva | Pregenaq | Prelynca | Regalbax | Rumbot | Utufar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Galica | Lyrica | Neo gaba | Nervax | Nervica | Neuromax | Pregadex | Zega</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lyrica</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Akugabalin | Antixiety | Cabalin | Epibalin | Epinoz | Gabarol | Gabica | Gablin | Ligaba | Lirapyn | Lyracip | Lyrica | Maxgalin | Nergab | Nervilin | Neurogab | Pergalin | Pregaba | Pregaben | Pregasafe | Pregatas | Prenura | Segabin sr | Seremax 150 sr | Seremax 75 sr | Syngab | Torgabalin | Xaar | Xyra | Zeegap</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A Gabalin | Anarica | Arica | Boryung pregabalin | Celpelin | Ctrica | Enpilin | Flinda | Fredik | Freeca | Gabalica | Gabamed | Gabaneuro | Gabarica | Gabarin | Gabelin | Hyundai pregabalin | I prel | Ilyca | J gaba | Jw pregabalin | K balin | Kabalin | Kerica | Lalaca | Lerica | Libarin | Licaneuro | Licapre | Ligabalin | Lipren | Liricure | Luruca | Lycabal | Lycabalin | Lycafree | Lycastar | Lyfrega | Lygarin | Lyleca | Lyprega | Lyribear | Lyrica | Lyrica cr | Neucapen | Neurobalin | Neurocover pg | Neurogabalin | Neuropain | Newrica | Nexrica | Pgabalin | Pgalin | Pgatin | Pharmrica | Plyrin | Pms pregabalin | Prady | Pralin | Preba | Prebal | Prebalin | Prebcy | Prebin | Precap | Predid | Prega | Pregaba | Pregaban | Pregal | Pregalin | Preganin | Pregaqual | Pregastar | Prenew | Preorin | Prep c | Prepentin | Prera | Prerica | Prestar | Pretin | Priga | Prilen | Prilin | Prin | Prireptol | Pririn | Procaban | Prokin | Qrorica | Ralican | Regaba | Ribalin | Ricabal | Ricafree | Rileap | Ripren | Samsung pregabalin | Sandoz pregabalin | Senrica | Seoul pregabalin | Sirica | Tds pregabalin | Teva pregaqual | Unica | Winrica | Yuhan pregabalin sr | Yurogaba</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Gablix | Lyrica | Nervax | Pregamax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Gabrika | Galica | Lyrica | Nervax | Neurexal | Plenica | Pms pregabalin | Pregabador | Pregadex | Pregastar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Linefor | Lyrica | Pragiola | Pregabalin acc | Pregabalin Alvogen | Pregabalin zentiva | Pregabaline cf | Pregamid | Siranalen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin ratiopharm | Pregabaline eg | Pregabaline mylan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Linefor | Lyrica | Pragiola | Pregabalin accord | Pregabalin ranbaxy | Pregabalin sandoz | Pregabalin stada | Pregabalin Teva | Pregabalin zentiva | Pregabalina terapia | Pregabaline aet | Pregagamma | Pregamid | Siranalen</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alyse | Edgar | Epigab | Epyca | Gabline | Gaphine | Gaprex | Lirapyn | Lyrica | Nervax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aityx | Aniernov | Ataxius | Betxcel | Bipalver | Brillior | Briobalyn | Ceutitac | Cyllin | Dismedox | Dominion | Gafinix | Galbax | Garbican | Gialtyn | Kineptia | Lirselude | Lucelan | Lyrica | Naleptor | Nevrika | Nuval | Oriol | Pregabalina | Prequinam | Prikul | Ramsun | Viravir | Zeugial | Zivador</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aloja | Brieka | Lygaba | Lyrica | Novugab | Pregabalin sandoz | Pregeb | Prelica | Prezel | Rewisca</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Larykul | Ligaba | Lirapyn | Lyrica | Neo gaba | Pregaba | Pregalad | Pregasafe | Pregaswisft | Theorica | Uruka | Zeegap</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin zentiva | Pregabaline Aurobindo | Pregabaline cf | Pregabaline mylan | Pregabaline sun | Pregabaline teva | Pregabaline wockhardt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin accord | Pregabalin aliud | Pregabalin krka | Pregabalin neuraxpharm | Pregabalin ratiopharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin pfizer</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Algabalina | Artofil | Axelia | Balile | Convult | Dolopat | Dolorelief | Elegya | Epibalin | Epibalin er | Ibancheck | Limiar | Lyrica | Lyridol | Martesia | Maxgalin | Neurum | Pillneur | Plenica | Prebalin | Prebictal | Precord | Pregabalina | Pregadol | Pregalab | Pregalex | Pregalip | Pregapharm | Pregavitae | Pregobin | Prestat | Pripax | Zeugial</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Convult | Funxion | Gabi | Gabica | Gablin | Gablurica | K barin | Ligaba | Nervagest | Neuroz | Pegablin | Pregabur | Pregadex | Pregalin | Pregasafe | Pregeb | Preneurin | Prepentin | Rhyma | Vexer | Zyzyx</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abalin | Abenaki | Ambrogab | Ampreg | Baliptic | Biogab | Blin | Breglin | Brulyn | Dologab | Dygab | Dynagab | Faasgablin | Fazogab | Freglin | G gab | Gabafit | Gabapex | Gabapil | Gabazon | Gabfast | Gabilis | Gabimor | Gabinal | Gabisave | Gabiun | Gabizam | Gablin | Gabmark | Gaboben | Gabolest | Gabpre | Gabrin | Gabrix | Gabur | Gben | Geogabalin | Gibli | Grepalin | Heflin | Higab | Hilin | Hygab | Irgab | J Baline | Jablin | Koirin | Lacpril | Laviga | Linba | Lingab | Lyribrain | Lyricowin | Medirica | Megab | Megabalin | Mygaba | Neoglan | Nergab | Nervica | Neugalin | Neugast | Neurica | Neurika | Neurob | Newgaba | Novagab | Novagab ds | Novatron | Novogab | Nugin | Nurica | Orgab | P gab | P gablin | Pacigab | Pagabin | Pangab | Pascal | Pegalin | Perjeb | Pgb neo | Pharmageb | Pre gax | Pre max | Preaed | Prebal | Prebalex | Prebel | Prebica | Prebrain | Pregaba | Pregabin | Pregabro | Pregalax | Pregalin | Pregastar | Preget | Pregsafe | Pregton | Pregy | Prejab | Preleptic | Prelin | Preneu | Prescot | Prewel | Prewell | Prica | Primemark | Priya | Reganel | Regapen | Reslorton | Reteric | Ricalinz | Roglin | Rushin | Sablin | Saigab | Scirica | Seipil | Spingab | Syngab | Ultragab | Uni gaba | Vesgab | Vyolen | Welgab | Xilica | Xrex | Zerica | Zoblin | Zorgab | Zureg</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Egzysta | Kartesada | Linefor | Lyrica | Naxalgan | Pragiola | Pregabalin accord | Pregabalin apotex | Pregabalin mylan | Pregabalin neuropharma | Pregabalin pfizer | Pregabalin sandoz | Pregabalin stada | Pregabalin zentiva | Pregabalin zentiva k.s. | Pregamid | Preglenix | Tabagine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Lyrica cr | Pregabalin extended release</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalina alter | Pregabalina aristo | Pregabalina Aurobindo | Pregabalina Aurovitas | Pregabalina Azevedos | Pregabalina Baldacci | Pregabalina Bluepharma | Pregabalina Ciclum | Pregabalina Cinfa | Pregabalina Farmoz | Pregabalina Gatica | Pregabalina Generis | Pregabalina GP | Pregabalina Jaba | Pregabalina kipa | Pregabalina lek | Pregabalina mylan | Pregabalina Pentafarma | Pregabalina Pharmakern | Pregabalina ratiopharm | Pregabalina Tecnigen | Pregabalina Tetrafarma | Pregabalina teva | Pregabalina Tolife | Pregabalina zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citoneuron | Martesia | Neurimeg | Neurum | Nuclene | Prebalin | Prebictal | Prefaxil | Pregabadin | Pregabalina bauel top | Pregabalina bioteng | Pregabalina eticos | Pregabalina imedic | Pregabalina kirei pharma | Pregabalina landa | Pregabalina phi | Pregabalina promepar | Pregabalina vivele | Pregabax | Pregal | Transfar | Zupinol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alyse | Gabica | Lebalix | Lyrica | Neo Gaba | Nervax | Pregadex | Prex (JPI) | Xyra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pragiola | Pregabalin accord | Pregabalin Sandoz GmbH | Pregabalin zentiva | Pregabalina Aurobindo | Pregabalina terapia | Pregamid | Siranalen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Algerika | Lyrica | Prabegin | Pragabalin canon | Pregabalin canon | Pregabalin Dr. Reddy | Pregabalin Medisorb | Pregabalin Nativ | Pregabalin richter | Pregabalin sz | Pregabalin zentiva | Pregabio | Prigabilon | Replica</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gabex | Lebalin | Lyrgaba | Lyrica | Nervax | Pms pregabalin | Prex | Zega</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Lyrica | Pregabalin 2care4 | Pregabalin accord | Pregabalin Accord Healthcare | Pregabalin eql pharma | Pregabalin krka | Pregabalin orion | Pregabalin ranbaxy | Pregabalin sandoz | Pregabalin Sandoz GmbH | Pregabalin stada | Pregabalin Teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Prebalin | Pregabalin sandoz | Pregaredi | Regadex | Rewisca</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lyrica | Pregabalin accord | Pregabalin belupo | Pregabalin krka | Pregabalin Sandoz GmbH | Pregabalin stada</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Brieka | Egzysta | Kartesada | Lyrica | Naxalgan | Pragiola | Preato | Pregabalin accord | Pregabalin belupo | Pregabalin mylan | Pregabalin sandoz | Pregabalin stada | Pregabalin Teva | Pregabalin zentiva | Pregagamma | Pregamid | Preglenix | Premed | Rabakir | Siranalen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Brillior | Larik | Lybalin | Lyrica | Nervica | Pebarin | Pobalin | Pregabalin sandoz | Prepentin | Prerica | Toprelin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aciryl | Adontag | Dolica | Edgar | Gabamim | Lydol | Lyrica | Nergesic | Nervica | Neuromed | Neuryl | Pregab | Prerica</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alyse | Galara | Gerica | Lypre | Lyrica | Neogaba | Neurica | Paden | Pagadin | Pagamax | Perge | Pirepsil | Prelica | Regapen | Snapline | Spesicor | Symra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bergalin | Lygaba | Lyrica | Phudialin | Pms pregabalin | Prebalin | Suculin | Syngexa | Tirica | Zeropin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Algerika | Egzysta | Gabalin | Gabana | Galara | Ligato | Linbag | Linefor | Lyrica | Maksgalin | Neogabin | Ogranij | Pregabalin darnitsa | Pregabalin richter | Pregabalin Teva | Pregabalin zn | Pregadol | Pregalon | Sudorega | Torgabalin | Zonic</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cabalin | Ligaba | Lirapyn | Lyrica | Neurogab | Neurokem | Pirav | Pregasafe | Pregatas | Pregavalex | Torgabalin | Zylin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gavin | Lyrica | Martesia | Nova | Prebictal | Pregax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dolnix | Gabarol | Martesia | Neurixa | Pegyt | Pralina | Prebictal | Prebral | Pregabalina | Pregasafe | Pregobin | Prelival | Xablin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Antivic | Cododamed | Craba | Febalin | Lirystad | Neuralmin | Pegaset | Regabin | Synapain</span>;</li>
<li>
<span class="countryCode">(YE)</span> <span class="country">Yemen</span><span class="countrySeparator">: </span><span class="drugName">Lygalin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Amrysin | Forrester pregabalin | Glovireg | Innrika | Nergil | Nervalin | Neuprog | Nubacap | Nurika | Pregabalin cipla | Pregabalin mylan | Pregabalin Teva | Regron | Timiril | Zanerva</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cabalin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lipapyn | Lirapyn | Lyrica | Prega | Pregaba</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23089176">
<a name="23089176"></a>Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. <i>Burns</i>. 2013;39(1):24-29. doi:10.1016/j.burns.2012.09.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23089176/pubmed" id="23089176" target="_blank">23089176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20466589">
<a name="20466589"></a>Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. <i>Sleep Med</i>. 2010;11(6):512-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/20466589/pubmed" id="20466589" target="_blank">20466589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24521108">
<a name="24521108"></a>Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. <i>N Engl J Med</i>. 2014;370(7):621-631.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24521108/pubmed" id="24521108" target="_blank">24521108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28967801">
<a name="28967801"></a>Arnold LM, McCarberg BH, Clair AG, et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. <i>Postgrad Med</i>. 2017;129(8):921-933. doi:10.1080/00325481.2017.1384691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28967801/pubmed" id="28967801" target="_blank">28967801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27475753">
<a name="27475753"></a>Arnold LM, Schikler KN, Bateman L, et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. <i>Pediatr Rheumatol Online J</i>. 2016;14(1):46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27475753/pubmed" id="27475753" target="_blank">27475753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28168835">
<a name="28168835"></a>Atıs G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. <i>Dermatol Ther</i>. 2017;30(2). doi:10.1111/dth.12459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28168835/pubmed" id="28168835" target="_blank">28168835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21398351">
<a name="21398351"></a>Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ</i>. 2011;342:d1199. doi:10.1136/bmj.d1199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21398351/pubmed" id="21398351" target="_blank">21398351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.<i> J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berns.1">
<a name="Berns.1"></a>Berns JS. Chronic kidney disease-associated pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin</i>
<i>Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37314034">
<a name="37314034"></a>Boehlke C, Joos L, Coune B, et al. Pharmacological interventions for pruritus in adult palliative care patients. <i>Cochrane Database Syst Rev</i>. 2023;4(2023):CD008320. doi:10.1002/14651858.CD008320.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/37314034/pubmed" id="37314034" target="_blank">37314034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28988943">
<a name="28988943"></a>Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. <i>Eur Neuropsychopharmacol</i>. 2017;27(12):1185-1215. doi:10.1016/j.euroneuro.2017.08.430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28988943/pubmed" id="28988943" target="_blank">28988943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21959031">
<a name="21959031"></a>Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. <i>Can J Psychiatry</i>. 2011;56(9):558-566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21959031/pubmed" id="21959031" target="_blank">21959031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482920">
<a name="21482920"></a>Bril V, England J, Franklin GM, et al. Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. <i>Neurology</i>. 2011;76(20):1758-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21482920/pubmed" id="21482920" target="_blank">21482920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22494020">
<a name="22494020"></a>Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. <i>Curr Med Res Opin</i>. 2012;28(6):1027-1037. doi:10.1185/03007995.2012.684044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/22494020/pubmed" id="22494020" target="_blank">22494020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalal.1">
<a name="Dalal.1"></a>Dalal S. Overview of pruritus in palliative care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18507657">
<a name="18507657"></a>De Smedt RH, Jaarsma T, van den Broek SA, Haaijer-Ruskamp FM. Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report. <i>Br J Clin Pharmacol</i>. 2008;66(2):327-328. doi:10.1111/j.1365-2125.2008.03196.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18507657/pubmed" id="18507657" target="_blank">18507657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26718698">
<a name="26718698"></a>El Kenany S, El Tahan MR. Effect of preoperative pregabalin on post-caesarean delivery analgesia: a dose-response study. <i>Int J Obstet Anesth</i>. 2016;26:24-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26718698/pubmed" id="26718698" target="_blank">26718698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21644108">
<a name="21644108"></a>Erdoğan G, Ceyhan D, Güleç S. Possible heart failure associated with pregabalin use: case report. <i>Agri</i>. 2011;23(2):80-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21644108/pubmed" id="21644108" target="_blank">21644108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fazio.2018">
<a name="Fazio.2018"></a>Fazio SB, Yosipovitch G. Pruritus: therapies for localized pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2019">
<a name="FDA.2019"></a>FDA Safety Alert. MedWatch. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin</a>. Published December 19, 2019. Accessed December 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.1">
<a name="Feldman.1"></a>Feldman E. Management of diabetic neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21368587">
<a name="21368587"></a>Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. <i>Int Clin Psychopharmacol</i>. 2011;26(4):213-220. doi:10.1097/YIC.0b013e32834519bd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21368587/pubmed" id="21368587" target="_blank">21368587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24769529">
<a name="24769529"></a>Fong T, Lee AJ. Pregabalin-associated heart failure decompensation in a patient with a history of stage I heart failure. <i>Ann Pharmacother</i>. 2014;48(8):1077-1081. doi:10.1177/1060028014530551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24769529/pubmed" id="24769529" target="_blank">24769529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27397522">
<a name="27397522"></a>Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. <i>Hemodial Int</i>. 2017;21(1):63-71. doi:10.1111/hdi.12455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27397522/pubmed" id="27397522" target="_blank">27397522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28057164">
<a name="28057164"></a>Foroutan N, Nikvarz N. Role of pregabalin in management of pruritus: a literature review. <i>J Pharm Pharm Sci</i>. 2016;19(4):465-474. doi:10.18433/J35K6N<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28057164/pubmed" id="28057164" target="_blank">28057164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29027197">
<a name="29027197"></a>Frey N, Bodmer M, Bircher A, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. <i>Epilepsia</i>. 2017;58(12):2178-2185. doi:10.1111/epi.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/29027197/pubmed" id="29027197" target="_blank">29027197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22822593">
<a name="22822593"></a>Gabapentin and pregabalin: abuse and addiction. <i>Prescrire Int</i>. 2012;21(128):152-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/22822593/pubmed" id="22822593" target="_blank">22822593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042886">
<a name="18042886"></a>Gajraj NM. Pregabalin: its pharmacology and use in pain management. <i>Anesth Analg</i>. 2007;105(6):1805-1815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18042886/pubmed" id="18042886" target="_blank">18042886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23128284">
<a name="23128284"></a>Gallagher R, Apostle N. Peripheral edema with pregabalin. <i>CMAJ</i>. 2013;185(10):E506. doi:10.1503/cmaj.121232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23128284/pubmed" id="23128284" target="_blank">23128284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23577077">
<a name="23577077"></a>Garassino MC, Piva S, La Verde N, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. <i>PLoS One.</i> 2013;8(4):e59981. doi:10.1371/journal.pone.0059981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23577077/pubmed" id="23577077" target="_blank">23577077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23859128">
<a name="23859128"></a>Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. <i>Sleep Medicine</i>. 2013;14(7):675-684. doi: 10.1016/j.sleep.2013.05.016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23859128/pubmed" id="23859128" target="_blank">23859128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24899755">
<a name="24899755"></a>Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. <i>Sleep</i>. 2014;37(4):635-643. doi:10.5665/sleep.3558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24899755/pubmed" id="24899755" target="_blank">24899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27643884">
<a name="27643884"></a>Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. <i>Int Clin Psychopharmacol</i>. 2017;32(1):49-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27643884/pubmed" id="27643884" target="_blank">27643884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30488008">
<a name="30488008"></a>Ghaly RF, Plesca A, Rana S, Candido KD, Knezevic NN. Gabapentin-related suicide: Myth or fact? <i>Surg Neurol Int</i>. 2018;9:210. doi:10.4103/sni.sni_420_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/30488008/pubmed" id="30488008" target="_blank">30488008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2018">
<a name="Goldenberg.2018"></a>Goldenberg DL. Initial treatment of fibromyalgia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21734588">
<a name="21734588"></a>Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. <i>Int Clin Psychopharmacol</i>. 2011;26(5):243-251. doi:10.1097/YIC.0b013e3283491fd5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21734588/pubmed" id="21734588" target="_blank">21734588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24182230">
<a name="24182230"></a>Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. <i>Med J Aust</i>. 2013;199(9):624-625. doi:10.5694/mja13.10769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24182230/pubmed" id="24182230" target="_blank">24182230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21747401">
<a name="21747401"></a>Guzelkucuk U, Duman I, Yılmaz B, Tan AK. Reversible post-pregabalin peripheral edema in a spinal cord injury patient. <i>Spinal Cord</i>. 2012;50(6):472-473. doi:10.1038/sc.2011.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21747401/pubmed" id="21747401" target="_blank">21747401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10199060">
<a name="10199060"></a>Hamer HM, Morris HH. Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants. <i>Cleve Clin J Med</i>. 1999;66(4):239-245. doi:10.3949/ccjm.66.4.239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/10199060/pubmed" id="10199060" target="_blank">10199060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33283264">
<a name="33283264"></a>Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease.<i> Cochrane Database Syst Rev</i>. 2020;12(12):CD011393. doi:10.1002/14651858.CD011393.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/33283264/pubmed" id="33283264" target="_blank">33283264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976337">
<a name="26976337"></a>Inoue A, Sawada Y, Ohmori S, et al. Maculopapular type drug eruption caused by pregabalin: A case and literature review. <i>Allergol Int</i>. 2016;65(3):351-352. doi:10.1016/j.alit.2016.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26976337/pubmed" id="26976337" target="_blank">26976337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29871945">
<a name="29871945"></a>Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. <i>J Am Soc Nephrol</i>. 2018;29(7):1970-1978. doi:10.1681/ASN.2018010096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/29871945/pubmed" id="29871945" target="_blank">29871945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21479999">
<a name="21479999"></a>Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? <i>Curr Pain Headache Rep</i>. 2011;15(3):164-169. doi:10.1007/s11916-011-0199-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21479999/pubmed" id="21479999" target="_blank">21479999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290532">
<a name="24290532"></a>Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies. <i>Eur Neuropsychopharmacol</i>. 2014;24(1):125-132. doi:10.1016/j.euroneuro.2013.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24290532/pubmed" id="24290532" target="_blank">24290532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521491">
<a name="27521491"></a>Kato K, Iwasaki Y, Onodera K, et al. Pregabalin- and azithromycin-induced rhabdomyolysis with purpura: An unrecognized interaction: A case report. <i>Int J Surg Case Rep</i>. 2016;26:221-223. doi:10.1016/j.ijscr.2016.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27521491/pubmed" id="27521491" target="_blank">27521491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23115467">
<a name="23115467"></a>Kaufman MB, Choy M. Pregabalin and simvastatin: first report of a case of rhabdomyolysis. <i>P T</i>. 2012;37(10):579-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/23115467/pubmed" id="23115467" target="_blank">23115467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36377169">
<a name="36377169"></a>Khan NJ; Wahaj; Haider S, Gilani H, Iqbal N, Ali SA, Abbasi MA. Comparing the efficacy and safety of pregabalin vs gabapentin in uremic pruritus in patients of chronic kidney injury undergoing haemodialysis. <i>J Ayub Med Coll Abbottabad</i>. 2022;34(3):524-527. doi:10.55519/JAMC-03-9395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/36377169/pubmed" id="36377169" target="_blank">36377169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26957874">
<a name="26957874"></a>Khan TM, Aziz A, Suleiman AK. Effectiveness of posthemodialysis administration of pregabalin (75 mg) in treatment resistance uremia pruritus. <i>J Pharm</i>
<i>Bioallied</i>
<i>Sci</i>. 2016a;8(1):74-76. doi:10.4103/0975-7406.171736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26957874/pubmed" id="26957874" target="_blank">26957874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27824127">
<a name="27824127"></a>Khan TM, Wu DB, Goh BH, Lee LH, Alhafez AA, Syed Sulaiman SA. An observational longitudinal study investigating the effectiveness of 75 mg pregabalin post-hemodialysis among uremic pruritus patients. <i>Sci Rep</i>. 2016b;6:36555. doi:10.1038/srep36555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27824127/pubmed" id="27824127" target="_blank">27824127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25864854">
<a name="25864854"></a>Koncicki HM, Brennan F, Vinen K, Davison SN. An approach to pain management in end stage renal disease: considerations for general management and intradialytic symptoms. <i>Semin Dial</i>. 2015;28(4):384-391. doi:10.1111/sdi.12372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25864854/pubmed" id="25864854" target="_blank">25864854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20938333">
<a name="20938333"></a>Lavand'homme PM, Roelants F. Evaluation of pregabalin as an adjuvant to patient-controlled epidural analgesia during late termination of pregnancy. <i>Anesthesiology</i>. 2010;113(5):1186-1191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/20938333/pubmed" id="20938333" target="_blank">20938333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26961752">
<a name="26961752"></a>Lockwood PA, Pauer L, Scavone JM, et al. The pharmacokinetics of pregabalin in breast milk, plasma, and urine of healthy postpartum women. <i>J Hum Lact</i>. 2016:0890334415626148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26961752/pubmed" id="26961752" target="_blank">26961752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19901102">
<a name="19901102"></a>Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. <i>J Clin Oncol</i>. 2010;28(4):641-647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19901102/pubmed" id="19901102" target="_blank">19901102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19737439">
<a name="19737439"></a>Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. <i>Int J Neuropsychopharmacol</i>. 2010;13(2):229-241. doi:10.1017/S1461145709990460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19737439/pubmed" id="19737439" target="_blank">19737439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lyrica.1">
<a name="Lyrica.1"></a>Lyrica (pregabalin) [prescribing information]. New York, NY: Parke-Davis, Division of Pfizer Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LyricaCR.1">
<a name="LyricaCR.1"></a>Lyrica CR (pregabalin) [prescribing information]. New York, NY: Parke-Davis; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18840008">
<a name="18840008"></a>Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. <i>Drugs</i>. 2008;68(15):2205-2223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18840008/pubmed" id="18840008" target="_blank">18840008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16981876">
<a name="16981876"></a>Málaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. <i>Epilepsia</i>. 2006;47(9):1576-1579. doi:10.1111/j.1528-1167.2006.00713.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/16981876/pubmed" id="16981876" target="_blank">16981876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27206757">
<a name="27206757"></a>Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus.<i> J Am Acad Dermatol</i>. 2016;75(3):619-625.e6. doi:10.1016/j.jaad.2016.02.1237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27206757/pubmed" id="27206757" target="_blank">27206757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19761281">
<a name="19761281"></a>McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. <i>Drugs Aging</i>. 2009;26(10):883-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/19761281/pubmed" id="19761281" target="_blank">19761281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21745832">
<a name="21745832"></a>Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. <i>Am J Hosp Palliat Care</i>. 2012;29(3):177-182. doi:10.1177/1049909111412539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21745832/pubmed" id="21745832" target="_blank">21745832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28716783">
<a name="28716783"></a>Mostacci B, Poluzzi E, D'Alessandro R, Cocchi G, Tinuper P; ESPEA Study Group. Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. <i>J Neurol Neurosurg Psychiatry</i>. 2018;89(2):223-224. doi:10.1136/jnnp-2017-31614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28716783/pubmed" id="28716783" target="_blank">28716783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25479151">
<a name="25479151"></a>Moulin D, Boulanger A, Clark AJ, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. <i>Pain Res Manag</i>. 2014;19(6):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25479151/pubmed" id="25479151" target="_blank">25479151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed June 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26382310">
<a name="26382310"></a>North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. <i>Menopause</i>. 2015;22(11):1155-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26382310/pubmed" id="26382310" target="_blank">26382310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37252752">
<a name="37252752"></a>North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/37252752/pubmed" id="37252752" target="_blank">37252752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ohman.1">
<a name="Ohman.1"></a>Ohman I, De Flon P, Tomson T. Pregabalin kinetics in the neonatal period, and during lactation. <i>Epilepsia</i>. 2011;52 (suppl 6):249-250. Abstract p824.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22266144">
<a name="22266144"></a>Ortega-Camarero MA, Avila R, Prados Castaño M, Piñero M, Quiralte J, Cimbollek S. Challenge-based pregabalin induced urticaria and angioedema. A case report. <i>Allergol Immunopathol (Madr)</i>. 2012;40(5):323. doi:10.1016/j.aller.2011.09.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/22266144/pubmed" id="22266144" target="_blank">22266144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695430">
<a name="18695430"></a>Page RL 2nd, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. <i>J Cardiovasc Med (Hagerstown)</i>. 2008;9(9):922-925. doi:10.2459/JCM.0b013e3282fb7629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/18695430/pubmed" id="18695430" target="_blank">18695430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27458286">
<a name="27458286"></a>Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.<i> J Clin Oncol.</i> 2016;34(27):3325-3345. doi:10.1200/JCO.2016.68.5206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27458286/pubmed" id="27458286" target="_blank">27458286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15206660">
<a name="15206660"></a>Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. <i>J Clin Psychopharmacol</i>. 2004;24(2):141-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/15206660/pubmed" id="15206660" target="_blank">15206660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28446648">
<a name="28446648"></a>Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. <i>Neurology.</i> 2017;88(21):2020-2025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/28446648/pubmed" id="28446648" target="_blank">28446648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999003">
<a name="27999003"></a>Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2017;40(1):136-154. doi:10.2337/dc16-2042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27999003/pubmed" id="27999003" target="_blank">27999003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Ahmed E, Keilson YY. Cancer pain management: role of adjuvant analgesics (coanalgesics). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25297834">
<a name="25297834"></a>Qu C, Xie Y, Qin F, Liu W. Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. <i>Int J Clin Pharm</i>. 2014;36(6):1138-1140. doi:10.1007/s11096-014-0026-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25297834/pubmed" id="25297834" target="_blank">25297834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307046">
<a name="11307046"></a>Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. <i>Clin Neuropharmacol</i>. 2001;24(2):103-105. doi:10.1097/00002826-200103000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/11307046/pubmed" id="11307046" target="_blank">11307046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12638396">
<a name="12638396"></a>Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. <i>J Clin Pharmacol</i>. 2003;43(3):277-283. doi:10.1177/0091270003251119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/12638396/pubmed" id="12638396" target="_blank">12638396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33311867">
<a name="33311867"></a>Ravindran A, Kunnath RP, Sunny A, Vimal B. Comparison of safety and efficacy of pregabalin versus gabapentin for the treatment of uremic pruritus in patients with chronic kidney disease on maintenance haemodialysis. <i>Indian J Palliat Care</i>. 2020;26(3):281-286. doi:10.4103/IJPC.IJPC_212_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/33311867/pubmed" id="33311867" target="_blank">33311867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25222364">
<a name="25222364"></a>Reid R, Abramson BL, Blake J, et al; Menopause and Osteoporosis Working Group; Society of Obstetricians and Gynaecologists of Canada. Managing menopause. <i>J Obstet Gynaecol Can</i>. 2014;36(9):830-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25222364/pubmed" id="25222364" target="_blank">25222364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santen.1">
<a name="Santen.1"></a>Santen R, Loprinzi C, Casper R. Menopausal hot flashes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29424197">
<a name="29424197"></a>Schiavo A, Stagnaro FM, Salzano A, et al. Pregabalin-induced first degree atrioventricular block in a young patient treated for pain from extrapulmonary tuberculosis. <i>Monaldi Arch Chest Dis</i>. 2017;87(3):838. doi:10.4081/monaldi.2017.838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/29424197/pubmed" id="29424197" target="_blank">29424197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sirven.1">
<a name="Sirven.1"></a>Sirven JI. Approach to the discontinuation of antiseizure medications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27546759">
<a name="27546759"></a>Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. <i>J Crit Care</i>. 2016;36:116-124. doi:10.1016/j.jcrc.2016.06.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27546759/pubmed" id="27546759" target="_blank">27546759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22909343">
<a name="22909343"></a>Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. <i>Nephrology (Carlton)</i>. 2012;17(8):710-717. doi:10.1111/j.1440-1797.2012.01655.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/22909343/pubmed" id="22909343" target="_blank">22909343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein M. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31604720">
<a name="31604720"></a>Thein OS, Sutton B, Thickett DR, Parekh D. Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. <i>BMJ Case Rep</i>. 2019;12(10):e231355. doi:10.1136/bcr-2019-231355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/31604720/pubmed" id="31604720" target="_blank">31604720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.1">
<a name="Tietze.1"></a>Tietze KJ. Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/image?topicKey=PULM%2F2888&amp;search=dexmedetomidine%20withdrawal&amp;imageKey=PULM%2F79667&amp;rank=5~150&amp;source=see_link" target="_blank">http://www.uptodate.com</a>. Accessed October 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24449062">
<a name="24449062"></a>Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. <i>J Neurol</i>. 2014;261(3):579-588. doi:10.1007/s00415-013-7239-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/24449062/pubmed" id="24449062" target="_blank">24449062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26447687">
<a name="26447687"></a>Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. <i>Chest</i>. 2016;149(3):639-648. doi:10.1378/chest.15-1271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/26447687/pubmed" id="26447687" target="_blank">26447687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27824228">
<a name="27824228"></a>Vestita M, Cerbone L, Calista D. Brachioradial pruritus in a 47-year-old woman treated with pregabalin. <i>G Ital Dermatol Venereol</i>. 2016;151(6):727-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27824228/pubmed" id="27824228" target="_blank">27824228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weisshaar.2019">
<a name="Weisshaar.2019"></a>Weisshaar E, Szepietowski JC, Dalgard F, et al; European Dermatology Forum; European Academy of Dermatology and Venereology. European guideline on chronic pruritus. https://www.edf.one/dam/jcr:9c925c23-fa0f-4765-8592-a86a75ce0ec3/GL_Chronic_pruritus.pdf. Published 2019. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22790094">
<a name="22790094"></a>Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. <i>Acta Derm Venereol</i>. 2012;92(5):563-581. doi: 10.2340/00015555-1400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/22790094/pubmed" id="22790094" target="_blank">22790094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults. <i>Neurology</i>. 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27194385">
<a name="27194385"></a>Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. <i>Neurology</i> 2016;86(24):2251-2257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/27194385/pubmed" id="27194385" target="_blank">27194385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25099523">
<a name="25099523"></a>Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. <i>Int Urol Nephrol</i>. 2015;47(1):161-167. doi:10.1007/s11255-014-0795-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/25099523/pubmed" id="25099523" target="_blank">25099523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21320112">
<a name="21320112"></a>Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. <i>Epilepsia</i>. 2011;52(4):826-836. doi:10.1111/j.1528-1167.2010.02966.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pregabalin-drug-information/abstract-text/21320112/pubmed" id="21320112" target="_blank">21320112</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9473 Version 662.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
